The Lancet Retracts Key Talc Safety Commentary
April 2026
Conflict of interest involving Johnson & Johnson consultant leads to the removal of a pivotal 1977 article used to defend against decades of litigation.
In a landmark move for scientific integrity, the prestigious medical journal The Lancet has officially retracted a 1977 unsigned commentary that served as a cornerstone for the cosmetics industry’s defense of talc safety for nearly 50 years. The retraction, published on March 25, 2026, follows the revelation of a "serious conflict of interest" involving its author, who was a paid consultant for Johnson & Johnson.
The 1977 article, titled "Cosmetic talc powder," concluded that there was "no reason to believe" consumer exposure to cosmetic talc led to cancer or lung function loss. However, an investigation by historians David Rosner and Gerald Markowitz recently identified the author as the late Dr. Francis JC Roe.
Newly released documents from legal discovery proceedings show that Roe, while a well-regarded cancer researcher, was an unacknowledged paid consultant for Johnson & Johnson at the time of writing. Evidence reveals that Roe provided an advanced copy of the commentary to the company’s medical director, Gavin Hildick-Smith, and incorporated industry feedback into the final text published by The Lancet.
The article provided the industry with "scientific legitimacy" to oppose early FDA efforts to regulate asbestos in talc during the 1970s. For decades, defense lawyers used the commentary in multimillion-dollar lawsuits to argue that the medical community considered cosmetic talc safe.
The retraction comes amid a massive legal crisis for Johnson & Johnson. The company has faced tens of thousands of lawsuits alleging that its talc-based powders caused cancer due to asbestos contamination. This retraction removes a critical piece of the "scientific consensus" J&J has relied upon in courtrooms for half a century.
The timing of The Lancet’s decision is particularly sensitive. In late 2024, the U.S. Food and Drug Administration (FDA) had proposed new regulations for asbestos testing in cosmetic talc. However, on November 28, 2025, the FDA abruptly withdrew the proposal, leaving the testing process for asbestos in cosmetic products largely unregulated. The editors of The Lancet stated that had they been aware of Roe’s undeclared competing interests in 1977, they would not have published the commentary. "Roe’s conflict of interest... was a clear breach of publishing ethics," the journal noted in its official retraction statement.
Nati Elkin
